Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.
Jim Bullard is CTO and Co-Founder. Prior to co-founding Pendulum, Jim served as a Senior Staff Scientist at Pacific Biosciences. He completed his Ph.D. in Biostatistics at the University of California, Berkeley. He likes experimental design, programming languages and taking long walks with his dog. "I feel fortunate to be working with smart motivated people on interesting problems. Building products that help people is incredibly motivating."
John Eid is the CSO and Co-Founder of Pendulum. John has led fundamental technology development for over a decade in diverse areas that include advanced microscopy, single molecule detection and analyses, automated data acquisition systems, biophysical system modeling, and genome sequencing applications. Prior to co-founding Pendulum, John was a Principal Scientist at Pacific Biosciences. John completed his postdoctoral research at the Roland Institute at Harvard University, his Ph.D. in Biophysics and Computational Biology at the University of Illinois, Urbana Champaign, and his B.S. in Applied and Engineering Physics from Cornell University.
Alfred Spormann joined the Scientific Advisory Board of Pendulum in 2016 and is a Professor in Civil and Environmental Engineering at Stanford University. Alfred specializes in the metabolism of anaerobic microbes in disease, bioenergy and bioremediation. Alfred has over 120 peer-reviewed publications in microbiology and disease and is a thought leader in metabolic characterization of microbes. Alfred received his Ph.D. from Philipps-University, Marburg.
Dr. Anne L. Peters is currently a professor OF CLINICAL MEDICINE at the Keck School of Medicine of the University of Southern California and the Director of the USC Clinical Diabetes Programs. She directs diabetes centers in Beverly Hills and in underserved East Los Angeles and works with the LA County Department of Health Services on a county-wide diabetes program. Dr. Peters earned her undergraduate degree from Wesleyan University located in Middletown, Connecticut and her medical degree from the Pritzker School of Medicine at the University of Chicago. She was in charge of the clinical diabetes programs at Cedars and then at UCLA before moving to USC. Dr. Peters has been a principal investigator on multiple clinical trials focusing on diabetes and diabetes prevention. In addition, she established the Community Diabetes Initiatives Research Center (CDI) in collaboration with Children's Hospital Los Angeles with funding from the Keck Foundation, JDRF, ADA, NIH, Rose Hills Foundation, California Nutrition Network, TrialNet, and the Helmsley Trust.
Dr. Carol Wysham is Clinical Professor of Medicine at the University of Washington School of Medicine and is a Clinical Endocrinologist at Rockwood Multicare Center for Diabetes and Endocrinology in Spokane, Washington. Her current areas of research interest include treatments for reduction of risk of cardiovascular and renal disease in patients with type 2 diabetes and improving delivery of care for diabetes. She has conducted numerous trials including the ACCORD, LEADER, EMPA-REG, CANVAS, TECOS and AIM-HIGH. She is a member of the American Diabetes Association and The Endocrine Society and a Fellow of the American College of Endocrinology and The American College of Physicians.
Dr. Mason is an Associate Professor of Integrative Functional Genomics, Clinical Genetics and Synthetic Biology at Weill Cornell Medical College in New York where he is a recognized leader in his field. He is well published and a frequent speaker in the areas of sequencing-based methods to generate cell-specific molecular maps of genetic, epigenetic, and transcriptional activity to provide multi-dimensional molecular portraits of development and disease. Dr. Mason has won the NIH’s Transformative R01 Award, the NASA Group Achievement Award, the Pershing Square Sohn Cancer Research Alliance Young Investigator award, the Hirschl-Weill-Caulier Career Scientist Award, the Vallee Scholar Award, the CDC Honor Award for Standardization of Clinical Testing, and the WorldQuant Foundation Scholar Award.
Ms. Kruger has been a certified nurse practitioner in diabetes at Henry Ford Health System in Detroit, MI, for more than 35 years. She earned her Master of Science in Nursing degree from Wayne State University in Detroit and her Bachelor of Science in Nursing degree from Boston College, in Boston, MA. Her role includes both clinical practice and research, and she is board-certified in both primary care and advanced diabetes management. Ms. Kruger has been a co-investigator on numerous studies of diabetes interventions and care, including the National Institutes of Health-funded multi-center EDIC and ACCORD trials. She lectures extensively throughout the United States on maximizing outcomes in diabetes and diabetes management. She is a past Chair of the American Diabetes Association (ADA) Research Foundation and has served on the ADA Research Policy Committee. She is also an ADA Past President, Health Care and Education.
Emeran Mayer joined as a Scientific and Medical Advisor to Pendulum in 2016. Emeran is a Gastroenterologist, Neuroscientist and Professor in the Departments of Medicine, Physiology and Psychiatry at the David Geffen School of Medicine at UCLA. He is the Executive Director of the G Oppenheimer Center for Neurobiology of Stress & Resilience and the co-director of the CURE: Digestive Diseases Research Center at UCLA. As one of the pioneers and leading researchers in the role of mind-brain-gut interactions in health and chronic disease, he has made major scientific contributions to the area of basic and translational enteric neurobiology with wide-ranging applications in clinical GI diseases and disorders. Emeran has been interviewed on National Public Radio, PBS and by many national and international media outlets including the Los Angeles Times, Atlantic magazine and Spiegel Online. He has spoken at UCLA TEDx on the Mysterious Origins of Gut Feelings in 2015, and his book The Mind Gut Connection has been published by Harper&Collins in July of 2016.
Eric Schadt Ph.D. has been the Head Scientific Advisor to Pendulum since its inception. He is founder and CEO of Sema4, a patient-centered predictive health company built on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. Dr. Schadt also serves as the Dean for Precision Medicine and Mount Sinai Professor in Predictive Health and Computational Biology at the Icahn School of Medicine at Mount Sinai. He was previously Founding Director of the Icahn Institute for Genomics and Multiscale Biology, and Professor and Chair of the Department of Genetics and Genomic Sciences. Dr. Schadt is an expert on constructing predictive models of disease that link molecular biology to physiology to enable clinical medicine. Over the past 20 years, he has built groups and companies (Merck, Rosetta, Sage Bionetworks, Pacific Biosciences, Icahn Institute, and now Sema4) to elucidate the complexity of human diseases. He has published more than 350 peer-reviewed papers in leading scientific journals and contributed to discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Now, with Centrellis™, Sema4’s innovative health intelligence platform, Dr. Schadt is using advanced network analysis to build better models of human health and deliver personalized insights for patients.
Dr. Pasricha is the Director of the Johns Hopkins Center for Neurogastroenterology, Professor of Medicine and Vice Chair of Medicine Innovation and Commercialization. Dr. Pasricha is a world-leading expert in gastroenterology whose research has focused on elucidating the underlying physiology and mechanisms driving a wide variety of diseases, including both those affecting the gut (IBS, gastroparesis, functional dyspepsia, chronic pancreatitis) and the gut-brain and gut-metabolic axes including mood disorders, Parkinson’s Disease, autism and diabetes. Dr. Pasricha has advanced the understanding of these diseases through his groundbreaking work in gastrointestinal motility, the enteric nervous system and visceral pain, endoscopic technology development, and functional understandings of the intestinal microbiome.
Dr. John Buse is the Verne S. Caviness Distinguished Professor, Chief of the Division of Endocrinology, Director of the Diabetes Center, Director of the NC Translational and Clinical Sciences Institute and Executive Associate Dean for Clinical Research at the University of North Carolina (UNC) School of Medicine in Chapel Hill. Dr. Buse received his MD and PhD from Duke University before training in internal medicine and endocrinology at the University of Chicago. His efforts combines clinical care, research, administration and teaching. He has received international recognition for innovative patient-centered care. He works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science towards clinical application. He serves as Director of the NC Translational and Clinical Sciences Institute working through a NIH-based consortium to accelerate the conversion of ideas and discoveries to products and policies for the improvement of health and well-being. Dr. Buse completed service as President for Medicine & Science at the American Diabetes Association in 2008 and as Chair of the National Diabetes Education Program in 2014.
Peter Turnbaugh is a Scientific Advisor to Pendulum and is an Assistant Professor of Department of Microbiology and Immunology for G.W. Hooper Research Foundation at University of California, San Francisco. He is also Faculty Director of Gnotobiotic Mouse Core Facility, a co-organizer of Bay Area Microbial Pathogenesis Symposium, and a member of the American Association for the Advancement of Science, American Society for Nutrition, American Gastroenterological Association, UCSF Diabetes Center and UCSF Nutrition and Obesity Research Center. Turnbaugh and his research group combine metagenomics and gnotobiotics (germ-free and intentionally-colonized mice) to study the impact of the gut microbiome on nutrition and drug metabolism. Prior to joining UCSF, Peter was a Bauer Fellow in the FAS Center for Systems Biology at Harvard University. He received a B.A. in Biochemistry, Biophysics, and Molecular Biology from Whitman College and a Ph.D. in microbial genomics from Washington University in Saint Louis.
Dr. Robert E. Ratner is the former Chief Scientific & Medical Officer for the American Diabetes Association where he led medical activities including research, clinical affairs, program recognition and certification, medical information and professional education. Dr. Ratner received his MD from Baylor College of Medicine in Houston, Texas where he also completed his Internal Medicine training. He underwent fellowship training in Endocrinology and Metabolism at Harvard Medical School and the Joslin Diabetes Center in Boston. He has served on the Board of Directors of the National Certification Board for Diabetes Education and the American Association of Diabetes Educators, and has served as the Chair of the Government Relations Committee and the Pregnancy Council of the American Diabetes Association.
Dietrich is the Professor and Chair of the Department of Human Genetics at the University of Pittsburgh Graduate School of Public Health. Dietrich is an American human geneticist and entrepreneur who works in personalized medicine, has published more than 140 peer-reviewed scientific articles in the scientific literature and served as the Chairman of the NIH Neuroscience Microarray Consortium for seven years. He sits on the Board of Directors of a number of non-profit academic institutions such as Sage Bionetworks and the Personalized Medicine Coalition. Dr. Stephan received his B.S. in Biology/Biochemistry from Carnegie Mellon University and his Ph.D. in Human Molecular Genetics from the University of Pittsburgh.